Selective and combined neurokinin receptor antagonists.
Gerspacher
Marc
M
Novartis Institutes for Biomedical Research Basel, Novartis Pharma AG, Switzerland. marc.gerspacher@pharma.novartis.com
D000818:Animals; D002493:Central Nervous System Diseases / Q000188:drug therapy; D004338:Drug Combinations; D005767:Gastrointestinal Diseases / Q000188:drug therapy; D006801:Humans; D008171:Lung Diseases / Q000188:drug therapy; D015288:Neurokinin A / Q000378:metabolism; D015287:Neurokinin B / Q000378:metabolism; D010146:Pain / Q000188:drug therapy; D018039:Receptors, Tachykinin / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000627:therapeutic use; D013373:Substance P / Q000378:metabolism; D014570:Urologic Diseases / Q000188:drug therapy; D014839:Vomiting / Q000188:drug therapy
D004338:Drug Combinations; D018039:Receptors, Tachykinin; D013373:Substance P; D015288:Neurokinin A; D015287:Neurokinin B